High Impact Publications Award

MUSC Hollings Cancer Center enthusiastically supports its members’ impactful discoveries and publications and has developed the High Impact Publications Award to recognize excellence on a yearly basis. Hollings leadership will select these publications from nominations that have appeared in high impact journals with a Hollings member as the first or a primary author. For any questions concerning eligibility or submitting a nomination, please contact Renee Steffen (steffenr@musc.edu).

Please use the nomination portal below to submit a publication for consideration.

Eligibility and Criteria | Review Committee | Timeline | Awardees

High Impact Publications

Nominations are due by midnight on Tuesday, October 1, 2024.

Eligibility and Criteria

  • Must be a full Hollings member.
  • Must be first or a primary author of the publication.
  • Work must have been completed at MUSC.
  • Must be cancer related, but preference will be given to translational science.
  • Nominations can be submitted by colleagues or self-nominations. Self-nominations are limited to one publication.
  • The publication must have appeared in a high impact journal or e-published within the past previous academic year (July 1 through June 30). Manuscripts will be accepted if they produce an official letter of acceptance.
  • Three publications will be honored per year for the previous academic year. One awardee will be chosen from each Hollings research program.
  • Awardees will receive the following:
    • $1,000 from their specific research program.
    • A framed plaque to be awarded at an Executive Committee meeting and displayed at the awardees' discretion.
    • A personalized nameplate on the plaque displayed outside the Hollings Cancer Center auditorium.

Review Committee

Review committee members were nominated by the Hollings research program leaders. Awardee decisions will be made based on a number of metrics including, but not limited to, impact factor and citation count.

  • Cancer Biology and Immunology: Joe Delaney, Ph.D., and Leonardo Ferreira, Ph.D.
  • Cancer Prevention & Control: Jennifer Dahne, Ph.D., and Evan Graboyes, M.D.
  • Developmental Cancer Therapeutics: Jen Wang, Ph.D., and John Wrangle, M.D.

Timeline

The deadline for nominations is Tuesday, October 1, 2024, by midnight. Selections will be made and awardees will be notified in November. To begin the nomination process, visit the portal found at the top of your screen.